Article Sidebar
Published:
Jul 12, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of sacubitril–valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels
Abstract
Purpose: To assess the effect of sacubitril–valsartan on chronic heart failure (CHF).
Methods: A total of sixty CHF patients were divided randomly into two groups of thirty patients each (conventional and sacubitril- valsartan groups, respectively). Conventional anti-heart-failure treatment was used in the conventional group, while the sacubitril– valsartan group received sacubitril–valsartan (25 mg) taken orally, twice daily, followed by up-titration to 100 mg, twice daily. After 3 months of treatment, the six-minute walking test (6-MWT), left ventricular ejection fraction (LVEF) scores, left ventricular end-diastolic diameters, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and NT-proBNP/brain natriuretic peptide (BNP) levels, treatment efficacy, and adverse cardiovascular events were evaluated.
Results: After three months of treatment, the level of serum NT-proBNP and NT-proBNP/BNP in the sacubitril–valsartan group was lower, while the levels of LVEF and 6-MWT were higher (p < 0.05), compared with the conventional group. Sacubitril-valsartan treatment had a better therapeutic effect than the conventional treatment, while readmission rate for heart failure was lower in the sacubitrilvalsartan treatment group (p < 0.05). Both LVEF and 6-MWT values had significantly negative correlation with NT-proBNP/BNP ratio.
Conclusions: The efficacy of sacubitril-valsartan in the treatment of CHF is significant and improves the short-term prognosis of patients. These findings will require validation in large multicentre trials and over a longer duration of study.
